[1]. Kumar, S.K., V. Rajkumar and R.A. Kyle, et al., Multiple myeloma. Nat Rev Dis Primers, 2017. 3: 17046.
[2]. Rollig, C., S. Knop and M. Bornhauser, Multiple myeloma. Lancet, 2015. 385(9983): 2197-208.
[3]. Tan, D., W.J. Chng and T. Chou, et al., Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncol, 2013. 14(12): e571-81.
[4]. Siegel, R.L., K.D. Miller and A. Jemal, Cancer statistics, 2019. CA Cancer J Clin, 2019. 69(1): 7-34.
[5]. Ailawadhi, S., K. Bhatia and S. Aulakh, et al., Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet? Curr Hematol Malig Rep, 2017. 12(4): 309-316.
[6]. Fakhri, B., M.A. Fiala and S.A. Tuchman, et al., Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Clin Lymphoma Myeloma Leuk, 2018. 18(3): 219-224.
[7]. Costa, L.J., I.K. Brill and E.E. Brown, Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. Cancer, 2016. 122(20): 3183-3190.
[8]. Fiala, M.A., J.D. Finney and J. Liu, et al., Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leuk Lymphoma, 2015. 56(9): 2643-9.
[9]. Kristinsson, S.Y., A.R. Derolf and G. Edgren, et al., Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden. J Clin Oncol, 2009. 27(12): 2073-80.
[10]. Chan, H. and R.J. Milne, Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. Br J Haematol, 2020. 188(5): 692-700.
[11]. Hong, S., L. Rybicki and D. Abounader, et al., Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant, 2016. 22(6): 1141-1144.
[12]. Ailawadhi, S., S. Jacobus and R. Sexton, et al., Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J, 2018. 8(7): 67.
[13]. Ganguly, S., S. Mailankody and S. Ailawadhi, Many Shades of Disparities in Myeloma Care. Am Soc Clin Oncol Educ Book, 2019. 39: 519-529.
[14]. Goldstein, D.A., J. Clark and Y. Tu, et al., A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget, 2017. 8(42): 71548-71555.
[15]. Liu, W., J. Liu and Y. Song, et al., Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol, 2019. 12(1): 22.
[16]. Rajkumar, S.V., M.A. Dimopoulos and A. Palumbo, et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol, 2014. 15(12): e538-48.
[17]. Durie, B.G., J.L. Harousseau and J.S. Miguel, et al., International uniform response criteria for multiple myeloma. Leukemia, 2006. 20(9): 1467-73.
[18]. Palumbo, A., H. Avet-Loiseau and S. Oliva, et al., Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol, 2015. 33(26): 2863-9.
[19]. Chng, W.J., A. Dispenzieri and C.S. Chim, et al., IMWG consensus on risk stratification in multiple myeloma. Leukemia, 2014. 28(2): 269-77.
[20]. Dhakal, B., A. Szabo and S. Chhabra, et al., Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol, 2018. 4(3): 343-350.
[21]. Stringhini, S., C. Carmeli and M. Jokela, et al., Socioeconomic status and the 25 x 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1.7 million men and women. Lancet, 2017. 389(10075): 1229-1237.
[22]. Gray, P.J., C.C. Lin and M.R. Cooperberg, et al., Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol, 2017. 71(5): 729-737.
[23]. Albano, J.D., E. Ward and A. Jemal, et al., Cancer mortality in the United States by education level and race. J Natl Cancer Inst, 2007. 99(18): 1384-94.
[24]. Attalla, K., D.J. Paulucci and K. Blum, et al., Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database. Urol Oncol, 2018. 36(1): 14.e17-14.e24.
[25]. Hwang, K.T., W. Noh and S.H. Cho, et al., Education Level Is a Strong Prognosticator in the Subgroup Aged More Than 50 Years Regardless of the Molecular Subtype of Breast Cancer: A Study Based on the Nationwide Korean Breast Cancer Registry Database. Cancer Res Treat, 2017. 49(4): 1114-1126.
[26]. Alter, D.A., K. Iron and P.C. Austin, et al., Socioeconomic status, service patterns, and perceptions of care among survivors of acute myocardial infarction in Canada. JAMA, 2004. 291(9): 1100-7.
[27]. Perry, A.M., A.M. Brunner and T. Zou, et al., Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. Cancer, 2017. 123(13): 2561-2569.
[28]. Walker, G.V., S.R. Grant and B.A. Guadagnolo, et al., Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol, 2014. 32(28): 3118-25.
[29]. Linder, G., F. Sandin and J. Johansson, et al., Patient education-level affects treatment allocation and prognosis in esophageal- and gastroesophageal junctional cancer in Sweden. Cancer Epidemiol, 2018. 52: 91-98.
[30]. Li, B.D., W.A. Brown and F.L. Ampil, et al., Patient compliance is critical for equivalent clinical outcomes for breast cancer treated by breast-conservation therapy. Ann Surg, 2000. 231(6): 883-9.
[31]. Quaglia, A., R. Lillini and C. Mamo, et al., Socio-economic inequalities: a review of methodological issues and the relationships with cancer survival. Crit Rev Oncol Hematol, 2013. 85(3): 266-77.
[32]. Biasoli, I., N. Castro and M. Delamain, et al., Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry. Int J Cancer, 2018. 142(5): 883-890.
[33]. Attal, M., V. Lauwers-Cances and C. Hulin, et al., Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med, 2017. 376(14): 1311-1320.